Berkeley, California August 3, 2022
Channel Medsystems, Inc., a medical device company whose mission is to empower every woman to take control of her health journey, today announced that Heather Knight has joined the company’s Board of Directors.
|“We are pleased to welcome Heather to our Board of Directors,” said Chief Executive Officer Ric Cote. “Heather will be a valuable addition as we continue to expand our company footprint and gain momentum in the commercialization of Cerene®. We are excited for her to bring her skills and experience to the board.”|
Ms. Knight is a proven and dynamic medtech veteran with a track record of success in setting strategic direction and leading large, dynamic organizations. She has succeeded in building long-term, internal and external partnerships at all organizational levels. She is currently the Global Business Unit (GBU) President at Baxter Healthcare and is responsible for multiple GBUs in addition to commercial efforts across the Americas. She has led significant growth for these businesses including the Americas integration efforts of Hillrom which Baxter acquired in 2021. Previously, Ms. Knight held various leadership roles at Covidien and then Medtronic, following its acquisition of Covidien.
“One in five women suffer from heavy menstrual bleeding (HMB) – but they shouldn’t have to,” said Ms. Knight. “I have closely followed Channel’s progress and development of the Cerene Cryotherapy Device for women with HMB. More women and their doctors need to know about their options, including the Cerene treatment which can be performed in the comfort and convenience of a doctor’s office. I look forward to contributing to this company dedicated to women’s healthcare, and to helping to drive awareness and adoption of its innovative solution for women with HMB.”
About Cerene Cryotherapy
Cerene is an in-office endometrial cryoablation treatment that safely and effectively reduces heavy menstrual bleeding while naturally minimizing pain without requiring general anesthesia. The Cerene FDA pivotal clinical study (“CLARITY”), published in The Journal of Minimally Invasive Gynecology, concluded that 90% of all patients experienced an improvement in bleeding symptoms and were satisfied with the procedure at 12 months following treatment. Additionally, results published in The Journal of Minimally Invasive Gynecology in November 2021 demonstrated that the use of cryoablation to treat the endometrium enabled the preservation of the uterine cavity, with visualization in 93% of evaluated patients, and the ability to evaluate for pathologic change in 96% of patients whose uterine cavities could be fully visualized.
About Channel Medsystems
Channel Medsystems® is a privately-held company dedicated to empowering every woman to take control of her health journey and live her best life. With a commitment to deliver innovative technologies that exceed the expectations of women and their gynecologists, Channel strives to develop easy-to-use, safe, and cost-effective medical devices, resulting in exceptional outcomes and superior patient comfort that are accessible to all women. Channel Medsystems, Inc. is headquartered in Berkeley, CA.
Important Safety Information
Cerene® Cryotherapy Device is indicated to ablate the endometrial lining of the uterus in premenopausal women with heavy menstrual bleeding due to benign causes for whom childbearing is complete. Pregnancy following the Cerene procedure can be dangerous; therefore, contraception must be used until menopause. The Cerene procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Cerene Cryotherapy Device. Temporary side effects may include cramping, nausea, vomiting, vaginal discharge and spotting. For detailed benefit and risk information, consult the Cerene Instructions for use (IFU) or your healthcare professional. Learn More